Biopharma Corp. wraps up latest acne product trial

BioPharmX Corp., a leading pharmaceutical company developing and promoting health products for the dermatology and women’s market, revealed it has completed the “last subject visit in its Phase 2b trial."

Following the completion, the company plans to report their data from the trial at the Alabama Dermatology Society’s Dermatology Summer Symposium this June in Florida.

“The Phase 2b study was a dose-finding clinical trial to assess the efficacy and safety of BPX-01 for the treatment of acne vulgaris,” a press release said. “The 12-week, multi-center, randomized, double-blind, three-arm, vehicle-controlled study involves 225 individuals, ages 9 to 40, who have moderate-to-severe inflammatory, non-nodular acne vulgaris.”

The drug, BPX-01[1], is a “non-oil-based topical gel with fully solubilized minocycline that can penetrate the skin to deliver the antibiotic to where acne develops in the pilosebaceous unit.”

To learn more, visit www.BioPharmX.com.